Unknown

Dataset Information

0

Görlich2003_RanGTP_gradient

ABSTRACT: This model represents a concentration gradient of RanGTP across the nuclear envelope. This gradient is generated by distribution of regulators of RanGTPase. We have taken a log linear plot of graphs generated by GENESIS and compared with the experimental graphs.

This model originates from BioModels Database: A Database of Annotated Published Models. It is copyright (c) 2005-2008 The BioModels Team.
For more information see the terms of use.

ORGANISM(S): Homo sapiens

SUBMITTER: Lucian Smith 

PROVIDER: MODEL4969417017 | biostudies-other |

SECONDARY ACCESSION(S): 12606574

REPOSITORIES: biostudies-other

Json Xml
altmetric image

Publications

Characterization of Ran-driven cargo transport and the RanGTPase system by kinetic measurements and computer simulation.

Görlich Dirk D   Seewald Michael J MJ   Ribbeck Katharina K  

The EMBO journal 20030301 5

Here, we analyse the RanGTPase system and its coupling to receptor-mediated nuclear transport. Our simulations predict nuclear RanGTP levels in HeLa cells to be very sensitive towards the cellular energy charge and to exceed the cytoplasmic concentration approximately 1000-fold. The steepness of the RanGTP gradient appears limited by both the cytoplasmic RanGAP concentration and the imperfect retention of nuclear RanGTP by nuclear pore complexes (NPCs), but not by the nucleotide exchange activit  ...[more]

Similar Datasets

Unknown Protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with Vemurafenib in combination with chromatin-targeting compounds (immunofluorescence dataset 3 of 4)
2017-01-20 | LDS-1370 | LINCS
Unknown FoxO3a nuclear-cytoplasmic pulsing dynamics in a mammary epithelial cell line following growth-factor treatment with varying ERK/AKT activation loads. Dataset 2 of 3: single-cell reporter pulsing metrics.
2017-05-02 | LDS-1383 | LINCS
Unknown Viability and apoptosis measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (viability/apoptosis dataset 1 of 2)
2017-01-20 | LDS-1366 | LINCS
Unknown LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 8 of 9: Calculated dose-response metrics for biological replicate 2
2017-03-14 | LDS-1380 | LINCS
Unknown MEMA AU565 Staining Set 100 (DMSO control)
2016-11-10 | LDS-1465 | LINCS
Unknown MEMA MCF10A Staining Set 2 no H3
2016-11-10 | LDS-1453 | LINCS
Unknown MEMA HMEC240L Staining Set 4
2016-11-10 | LDS-1439 | LINCS
Unknown LINCS MCF 10A Common Project: Rolling-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 2 of 15: End-point cell counts and normalized growth rate inhibition values for all technical replicates of biological replicate 2.
2017-05-12 | LDS-1409 | LINCS
Unknown Phosphorylation state and protein levels measured by imaging in BRAF(V600E/D) melanoma cell lines following treatment with combinations of two compounds (immunofluorescence dataset 2 of 4)
2017-01-20 | LDS-1369 | LINCS
Unknown LINCS MCF 10A Common Project: Fixed-time-point sensitivity measures of the MCF 10A breast cell line to 8 small molecule perturbagens. Dataset 2 of 9: Cell count and normalized growth rate inhibition values for biological replicate 2
2017-02-07 | LDS-1374 | LINCS